Cargando…

COVID-19 Vaccine Failure in a Patient with Multiple Sclerosis on Ocrelizumab

Vaccines will play a key role in ending the COVID-19 pandemic. Vaccination against infections remains an important part of the management of patients with multiple sclerosis. However, there are limited data about the safety and efficacy of the currently available COVID-19 mRNA vaccines in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chilimuri, Sridhar, Mantri, Nikhitha, Gongati, Sudharsan, Zahid, Maleeha, Sun, Haozhe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002140/ https://www.ncbi.nlm.nih.gov/pubmed/33806646 http://dx.doi.org/10.3390/vaccines9030219

Ejemplares similares

COVID-19 vaccine failure in a patient on rituximab therapy
por: Chilimuri, Sridhar, et al.
Publicado: (2021)

BNT162b2 mRNA Vaccine Interference with Co-Administration of Tdap Vaccine
por: Chilimuri, Sridhar, et al.
Publicado: (2021)

Potential predictors of outcomes among hospitalized COVID-19 patients treated with convalescent plasma: a single-center study
por: Chilimuri, Sridhar, et al.
Publicado: (2021)

Use of Monoclonal Antibodies Therapy for Treatment of Mild to Moderate COVID-19 in 4 Patients with Rheumatologic Disorders
por: Franchin, Giovanni, et al.
Publicado: (2021)

Impact of Prediabetes and Type-2 Diabetes on Outcomes in Patients with COVID-19
por: Makker, Jasbir, et al.
Publicado: (2021)

Role of body mass index in outcomes of patients hospitalized with COVID‐19 illness
por: Zahid, Maleeha, et al.
Publicado: (2022)

Association of smoking status with outcomes in hospitalised patients with COVID-19
por: Adrish, Muhammad, et al.
Publicado: (2020)

The Association of Renin-Angiotensin-Aldosterone System Inhibitors With Outcomes Among a Predominantly Ethnic Minority Patient Population Hospitalized With COVID-19: The Bronx Experience
por: Adrish, Muhammad, et al.
Publicado: (2020)

Implementation and outcomes of monoclonal antibody infusion for COVID-19 in an inner-city safety net hospital: A South-Bronx experience
por: Chilimuri, Sridhar, et al.
Publicado: (2022)

Fr008 THE CLINICAL SIGNIFICANCE OF ELEVATED LIPASE LEVELS IN COVID-19 PATIENTS - A LARGE RETROSPECTIVE COHORT STUDY
por: Nayudu, Suresh Kumar, et al.
Publicado: (2021)

Mo1330: THE IMPACT OF COVID-19 ON ALCOHOLIC LIVER DISEASES IN A PREDOMINANTLY AFRICAN AMERICAN AND HISPANIC COMMUNITY
por: Sun, Haozhe, et al.
Publicado: (2022)

Clostridioides difficile Infection and Liver Cirrhosis – A Retrospective, Cohort Study
por: Mantri, Nikhitha, et al.
Publicado: (2021)

Predictors of Mortality in Adults Admitted with COVID-19: Retrospective Cohort Study from New York City
por: Chilimuri, Sridhar, et al.
Publicado: (2020)

COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
por: Buttari, Fabio, et al.
Publicado: (2021)

The Incidence and Mortality Impact of Gastrointestinal Bleeding in Hospitalized COVID-19 Patients
por: Makker, Jasbir, et al.
Publicado: (2021)

COVID-19 in ocrelizumab-treated people with multiple sclerosis
por: Hughes, Richard, et al.
Publicado: (2021)

Peritoneal Lymphomatosis: The Great Mimicker
por: Shaikh, Danial H, et al.
Publicado: (2021)

COVID-19-Vaccine-Pfizer-BioNTech/ocrelizumab: Vaccine failure: case report
Publicado: (2021)

COVID-19 in the Healthy Patient Population: Demographic and Clinical Phenotypic Characterization and Predictors of In-Hospital Outcomes
por: Ronderos Botero, Diana Maria, et al.
Publicado: (2020)

Chronic hepatitis-C infection in COVID-19 patients is associated with in-hospital mortality
por: Ronderos, Diana, et al.
Publicado: (2021)

Ocrelizumab: A Review in Multiple Sclerosis
por: Lamb, Yvette N.
Publicado: (2022)

Gastric Metastasis 5 Years after Primary Invasive Lobular Adenocarcinoma of the Breast
por: Shin, Dongmin, et al.
Publicado: (2023)

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
por: Rolfes, Leoni, et al.
Publicado: (2021)

Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab
por: Habek, Mario, et al.
Publicado: (2022)

Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
por: Cellerino, Maria, et al.
Publicado: (2021)

Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab
por: Suwanwongse, Kulachanya, et al.
Publicado: (2020)

Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab
por: Pedotti, Rosetta, et al.
Publicado: (2021)

Ocrelizumab: a new milestone in multiple sclerosis therapy
por: Mulero, Patricia, et al.
Publicado: (2018)

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
por: Turner, Benjamin, et al.
Publicado: (2019)

Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology
por: Mancinelli, Chiara Rosa, et al.
Publicado: (2021)

Pregnancy outcome following exposure to ocrelizumab in multiple sclerosis
por: Chey, Shin Yee, et al.
Publicado: (2022)

Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients
por: Akgün, Katja, et al.
Publicado: (2022)

COVID-19 in persons with multiple sclerosis treated with ocrelizumab – A pharmacovigilance case series
por: Hughes, Richard, et al.
Publicado: (2020)

Acute cerebellitis requiring posterior fossa decompression after COVID-19 vaccination in an ocrelizumab-treated patient with multiple sclerosis
por: Brecl Jakob, Gregor, et al.
Publicado: (2022)

A Rare Case of Colonic Sarcoidosis Presenting as a Mass
por: Sun, Haozhe, et al.
Publicado: (2020)

Ocrelizumab-induced vulvovaginal pyoderma gangrenosum in a patient with relapsing-remitting multiple sclerosis
por: Klumpp, Annika, et al.
Publicado: (2022)

New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab
por: Frau, Jessica, et al.
Publicado: (2018)

Ocrelizumab Depletes CD20(+) T Cells in Multiple Sclerosis Patients
por: Gingele, Stefan, et al.
Publicado: (2018)

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
por: Barkhof, Frederik, et al.
Publicado: (2019)

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
por: Hauser, Stephen L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oouqbprijtbkpv2moqs7un16n8